Weight change and lipoprotein particle concentration and particle size: a cohort study with 6.5-year follow-up.
OBJECTIVE
Obesity and overweight are related to unfavourable lipoprotein subclass profiles. Here we studied the relation between weight change and lipoprotein particle concentrations and sizes in a general population cohort in a longitudinal setting.


METHODS
The cohort included 683 adults with a 6.5-year follow-up. Lipoprotein particle subclasses and mean particle sizes of VLDL, LDL, and HDL were measured by nuclear magnetic resonance spectroscopy.


RESULTS
During the follow-up period, a weight loss of at least 5% was associated with decreased particle concentrations of all apoB-containing subclasses and increased concentrations of large HDL particles. Coherently, weight gain (≥5%) was associated with increases in all apoB-containing subclasses and decreases in total and medium HDL particle concentrations. The relatively largest increase occurred for large HDL particle concentration (24.1%, 95% CI 15.8-32.5) in weight loss and for large VLDL particle concentration (33.0%, 19.6-46.4) in weight gain. Weight change correlated positively with changes in apoB-containing lipoprotein particle concentrations and also with the change in average VLDL particle size. Negative correlations were found between weight change and the change in average LDL (r = -0.10) and HDL (r = -0.32) particle size, but not between weight change and total HDL particle concentration.


CONCLUSIONS
Moderate weight loss is related to favourable and weight gain to unfavourable changes in lipoprotein subclass profiles. These population level findings underline the importance of weight control as a modifier of cardiovascular risk factors.
Institute of Public Health and Clinical Nutrition, Primary Health Care, School of Medicine, University of Eastern Finland, Kuopio, Finland. pekka.mantyselka@uef.fi
Pekka
P
Mäntyselkä
Hannu
H
Kautiainen
Juha
J
Saltevo
Peter
P
Würtz
Pasi
P
Soininen
Antti J
AJ
Kangas
Mika
M
Ala-Korpela
Mauno
M
Vanhala
D000328:Adult; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D016014:Linear Models; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008137:Longitudinal Studies; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000453:epidemiology / Q000503:physiopathology; D050177:Overweight / Q000097:blood* / Q000453:epidemiology / Q000503:physiopathology; D010316:Particle Size; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D015430:Weight Gain; D015431:Weight Loss
D015415:Biomarkers; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL